

BIDIRECTIONAL CONVERSION OF GALANTHAMINE AND CRININE TYPE HETEROCYCLES

Matthias Treu,^a Stefan Welzig,^b and Ulrich Jordis*^a

^a Department of Organic Chemistry, Vienna University of Technology

Getreidemarkt 9/154, A-1060 Vienna, Austria

ujordis@pop.tuwien.ac.at


^b Sanochemia Pharmazeutika AG, 2491 Neufeld, Austria

Abstract – The conversion of galanthamine-type molecules into crinine-type compounds and *vice versa* has been accomplished by a ring opening-Michael addition-cascade of a galanthamine-type secondary amine and a crinine-type quaternary ammonium salt.

INTRODUCTION

Galanthamine (or galantamine, Reminyl[®]) is a tertiary alkaloid acetylcholinesterase inhibitor (AChE) which has been approved in several countries for treating symptoms of Alzheimer's type senile dementia.^{1,2} Detailed investigations on a side product from the deformylation of bromoformylnarwedine (**7**) revealed the formation of the oxocrinine analog (**9**). This led to further studies in this field with regard to the biological properties – specially AChE and BChE inhibition – of the target compounds.^{3,4} Various derivatives and analogs of crinine (**1**) have previously been isolated as natural products. Particularly crinine itself was a focal point of interest: (+)-Crinine ((+)-**1**) has been extracted from the bulbs of *Pancreasium maritimum*,⁵ *Hippeastrum-hybrides*,⁶ *Hymenocallis calathina*,⁷ *Nerine corusca* and *Pancreatium illyricum*,⁸ from *Hippeastrum vittatum*,⁹ *Rhodophiala bifida*¹⁰ and from the blossoms of *Lycoris radiata*.¹¹ (-)-Crinine ((-)-**1**) was found in bulbs of *Ammocharis tinneana*,¹² *Calostemma purpureum*,¹³ *Brunsvigia radulosa*,¹⁴ *Crinum powellii*,^{15,16} *Nerine bowdenii*,¹⁶ *Buphane fischeri*,¹⁷ *Crinum moorli*,^{16,18} *Crinum asiaticum* and *Crinum defixum*.¹⁹ Furthermore the isolation of crinine-type natural products was reported: Oxocrinine (**2**) was extracted from *Crinum americanum*,²⁰ powellamine (**3**) from bulbs of *Crinum powellii*,²¹ maritidine (**4**) from *Narcissus tazetta*²² and from *Zephyranthes rosea*.²³ Demethylmaritidine (**5**) was found in bulbs of *Hymenocallis rotata*²⁴ and epivittatine (**6**) in *Boophone flava*.²⁵ (see Scheme 1)

Scheme 1



The synthetic approaches²⁶ to members of the crinine (**1**) and maritidine (**4**) family are divided into two sections: The key step of the first strategy comprises the formation of the bridged ring system by a Pictet-Spengler type cyclization reaction starting from suitable phenylpyrrolidines or phenylindolines,²⁷⁻³⁷ whereas the transformation of benzazepine derivatives into crinine analogs by an intramolecular Michael addition represents the second synthetic pathway.³⁸⁻⁴⁴ Only a few quarternary crinium salts are documented.^{8,9,15,18,21,45} Although Wildman⁴⁶ mentions the instability of such compounds under basic conditions, a controlled transformation into galanthamine-type products has not yet been considered.


RESULTS AND DISCUSSION

When bromoformylnarwedine (**7**) – an intermediate from the industrial galanthamine synthesis – was treated with concentrated HCl, the main product (**8**) was obtained in 74% yield accompanied by a small amount of compound (**9**). **8** could be converted into **9** by refluxing it in ethanol in presence of CaCl₂ with a yield of 71%. The appearance of a phenolic proton, a shift of the olefinic protons and a change of the peak pattern of the protons next to the nitrogen in a ¹H NMR spectrum indicated the formation of the crinine-type compound (**9**) by a ring opening of the furane moiety with concomitant formation of the bridged substructure in a retro-Michael-Michael-addition-cascade. Reduction of the enone (**9**) with L-Selectride[®] gave the allyl alcohol (**10**) in a yield of 69%, which was debrominated using a freshly prepared copper-zinc-couple⁴⁷ in presence of CaCl₂ to yield the crinine analog (**11**) of galantamine with a yield of 79% (see Scheme 2).


For the conversion of a crinine-type molecule into a galanthamine-type compound, a Hofmann degradation of the quarternary salt (**12**) was envisioned. Thus ketone (**9**), which was almost insoluble in common organic solvents including DMF or DMSO, was dissolved in HMPTA and treated with an

excess of methyl iodide to form the crystalline quarternary salt (**12**). When **12** was treated with NaOH in aqueous ethanol, bromonarwedine (**13**) was formed in a 50% yield and found to be identical with a reference sample.³ (see Scheme 3).

Scheme 2



Scheme 3



CONCLUSION

To summarize, we have performed the conversion of a galanthamin-type molecule into its crinine analog and *vice versa*. Interestingly, compound (**10**) exhibited the same BChE activity as galanthamine without any AChE inhibition. (see Table 1).

Compound	AChE inhibition [μmol/mL]	BChE inhibition [μmol/mL]
10	> 200	18
11	> 200	29
Gаланthamine (Reminyl®)	2.3	18

Table 1

EXPERIMENTAL

General: Melting points were measured on a Kofler melting point. ^1H and ^{13}C NMR-spectra were recorded on a Bruker AC-200 (200 MHz) pulse Fourier-transform NMR spectrometer in CDCl_3 or DMSO-d_6 using tetramethylsilane as an internal standard. Thin layer chromatography (TLC) was performed on precoated plates (Merck TLC aluminum sheets silica 60 F_{254}) with detection by UV light or with phosphomolybdic acid in aqueous EtOH by heating. All reactions were magnetically stirred under an argon atmosphere. MPLC (medium pressure liquid chromatography) was performed using SiO_2 (Baker), a LC-8A pump (Shimadzu), a SPD-6AV UV-detector (Shimadzu) and Büchi glass columns.

(4a*R,8a*R**)-1-Bromo-4a,5,9,10,11,12-hexahydro-3-methoxy-6*H*-benzofuro[3a,3,2-*ef*][2]benzazepin-6-one (8).** (4a*R**,8a*R**)-1-Bromo-4a,5,9,10-tetrahydro-3-methoxy-6-oxo-6*H*-benzofuro[3a,3,2-*ef*][2]benzazepine-11(12*H*)-carboxaldehyde⁴⁸ (40.0 g, 105.7 mmol) was refluxed in toluene (1100 mL) / conc. HCl (500 mL) under vigorous stirring for 24 h. The precipitate of the crude **8** * HCl was collected by filtration and washed with EtOAc (3 x 100 mL). The organic layer was separated and extracted with 2 N HCl (3 x 150 mL). The combined aqueous layers were washed with EtOAc (2 x 150 mL), the crude **8** * HCl (shown to contain small amounts of **9** by TLC) was added and the pH was adjusted to 12 with conc. NaOH, the precipitate of **8** was collected by filtration, washed with Et_2O (2 x 100 mL) and recrystallized from MeOH (1000 mL). Yield: colorless crystals, 27.38 g (74%), mp 192 – 194 °C (MeOH); ^1H NMR (CDCl_3): δ 7.05 (d, J = 10.7 Hz, 1H), 6.90 (s, 1H), 5.90 (d, J = 10.7 Hz, 1H), 4.36 – 4.62 (m, 1H), 4.40 (d, J = 16.4 Hz, 1H), 3.90 (d, J = 16.4 Hz, 1H), 3.75 (s, 3H), 3.10 - 3.35 (m, 2H), 2.95 (d, J = 16.0 Hz, 1H), 2.75 (d, J = 16.0 Hz, 1H), 1.90 - 2.15 (m, 2H); ^{13}C NMR (CDCl_3): δ 146.6 (s), 144.8 (d), 143.7 (s), 132.0 (s), 129.6 (s), 126.6 (d), 116.0 (d), 112.5 (s), 87.9 (d), 55.9 (q), 51.3 (t), 49.5 (t), 45.6 (s), 37.0 (t), 36.3 (t).

(4a α ,5 β ,10b β)-7-Bromo-4,4a-dihydro-10-hydroxy-9-methoxy-3*H*,6*H*-5,10b-ethanophenanthridine-3-one (9). **8** (3.00 g, 8.57 mmol) and CaCl_2 (1.50 g, 13.5 mmol) in 70% EtOH (120 mL) were stirred under reflux for 3 h. The mixture was concentrated *in vacuo* to a volume of 50 mL and cooled to 4 °C. The precipitate was filtered, dissolved in CHCl_3 (50 mL)/MeOH (50 mL) and treated with charcoal (0.3 g). After filtration and concentration *in vacuo*, the solid was collected and washed with Et_2O (2 x 50 mL).

Yield: colorless crystals, 2.13 g (71%), mp 219 – 224 °C (decomp); ¹H NMR (DMSO-d₆): δ 9.10 (br, 1H), 7.87 (d, *J* = 11.1 Hz, 1H), 7.08 (s, 1H), 5.81 (d, *J* = 11.1 Hz, 1H), 3.90 (d, *J* = 16.5 Hz, 1H), 3.75 (s, 3H), 3.55 (d, *J* = 16.5 Hz, 1H), 3.45 – 2.45 (m, 4H), 2.42 – 1.68 (m, 3H); ¹³C NMR (DMSO-d₆): δ 197.8 (s), 155.6 (d), 147.6 (s), 142.9 (s), 129.3 (s), 126.6 (s), 123.3 (d), 113.7 (s), 109.7 (d), 64.1 (d), 56.2 (q), 55.9 (t), 53.1 (t), 42.8 (s), 39.8 (t), 38.1 (t). Anal. Calcd for C₁₆H₁₆NO₃Br*0.33 H₂O: C, 53.95; H, 4.53; N 3.93. Found: C, 53.98; H, 4.53; N, 3.78.

(4aα,5β,10bβ)-7-Bromo-4,4a-dihydro-9-methoxy-3*H*,6*H*-5,10b-ethanophenanthridine-3,10-diol (10).

To a suspension of **9** (800 mg, 2.28 mmol) in anhydrous THF (10 mL) L-Selectride® (1 M in THF, 15 mL, 15 mmol) was added at rt. The solution was stirred for 1.5 h at this temperature, then 0.5 N HCl (5 mL) was added. The mixture was concentrated to a volume of 5 mL *in vacuo* and partitioned between water (5 mL) and CHCl₃ (20 mL)/MeOH (2 mL). The aqueous layer was extracted with CHCl₃/10 % MeOH (5 x 30 mL), the combined organic layers were washed with water (1 x 20 mL) and brine (1 x 20 mL), dried (Na₂SO₄) and filtered. After concentration *in vacuo*, the residue was purified by flash chromatography (SiO₂, CHCl₃ : MeOH : NH₃ = 89 : 10 : 1) and recrystallized from MeOH (5 mL). Yield: colorless crystals, 553 mg (69%), mp 216 - 219 °C (decomp) (MeOH); ¹H NMR (DMSO-d₆): δ 7.01 (s, 1H), 6.66 (d, *J* = 9.8 Hz, 1H), 5.46 (d, *J* = 9.8 Hz, 1H), 4.30 – 4.14 (m, 1H), 3.92 (d, *J* = 17.8 Hz, 1H), 3.86 (s, 3H), 3.62 (d, *J* = 17.8 Hz, 1H), 3.39 – 3.19 (m, 1H), 2.93 – 2.67 (m, 2H), 2.50 (s, 1H), 2.39 – 2.21 (m, 1H), 2.19 – 1.99 (m, 1H), 1.88 – 1.66 (m, 1H), 1.50 – 1.22 (m, 1H); ¹³C NMR (DMSO-d₆): δ 147.6 (s), 143.8 (s), 131.1 (d), 130.9 (s), 130.8 (d), 121.6 (s), 113.3 (d), 109.4 (s), 66.7 (d), 63.4 (d), 56.2 (q), 54.8 (t), 52.5 (t), 48.6 (s), 42.9 (t), 31.5 (t). Anal. Calcd for C₁₆H₁₈NO₃Br: C, 54.56; H, 5.15; N 3.98. Found: C, 54.61; H, 5.14; N, 3.87.

(4aα,5β,10bβ)-4,4a-Dihydro-9-methoxy-3*H*,6*H*-5,10b-ethanophenanthridine-3,10-diol (11). Zinc powder (300 mg) and CuI (300 mg) in water (4 mL)/EtOH (4 mL) were sonicated for 45 min under argon. **10** (200 mg, 0.57 mmol) and CaCl₂ (150 mg, 1.35 mmol) were added, and the mixture was refluxed for 12 h. The suspension was filtered and concentrated, and the residue was purified by flash chromatography (SiO₂, CHCl₃ : MeOH : NH₃ = 89 : 10 : 1) and recrystallized from MeOH (2 mL). Yield: 122 mg (79%), mp 234 – 239 °C (decomp) (MeOH); ¹H NMR (DMSO-d₆): δ 8.37 (br, 1H), 6.77 - 6.62 (m, 2H), 6.41 (d, *J* = 9.8 Hz, 1H), 5.42 (d, *J* = 9.8 Hz, 1H), 4.83 (br, 1H), 4.31 – 4.17 (m, 1H), 4.04 (d, *J* = 17.8 Hz, 1H), 3.73 (s, 3H), 3.47 (d, *J* = 17.8 Hz, 1H), 3.20 – 3.00 (m, 1H), 2.73 – 2.40 (m, 2H), 2.32 – 1.91 (m, 2H), 1.72 – 1.20 (m, 3H); ¹³C NMR (DMSO-d₆): δ 146.0 (s), 143.7 (s), 132.5 (d), 130.2 (d), 129.9 (s), 124.9 (s), 115.8 (d), 109.4 (d), 67.1 (d), 64.1 (d), 55.8 (q), 54.6 (t), 52.3 (t), 42.7 (s), 41.1 (t), 32.2 (t). Anal. Calcd for C₁₆H₁₉NO₃: C, 70.31; H, 7.01; N 5.12. Found: C, 70.12; H, 6.97; N, 5.20.

(4aα,5β,10bβ)-7-Bromo-4,4a-dihydro-10-hydroxy-9-methoxy-5-methyl-3-oxo-3*H*,6*H*-5,10b-ethanophenanthridinium iodide (12). To **9** (500 mg, 1.42 mmol) in anhydrous HMPTA (10 mL) methyl iodide

(232 mg, 1.63 mmol) was added at 15 °C, and the mixture was stirred at this temperature for 12 h. The solution was poured into EtOAc (75 mL)/Et₂O (75 mL), and the precipitate was collected by filtration and washed with Et₂O (3 x 20 mL). Yield: 614 mg (92%) colorless crystals. mp 195 – 197 °C (decomp); Due to broad line width no satisfying ¹H NMR-data could be obtained. ¹³C NMR (DMSO-d₆): δ 193.8 (s), 151.2 (d), 148.7 (s), 143.3 (s), 127.2 (d), 124.5 (s), 117.7 (s), 115.2 (d), 109.2 (s), 69.6 (q), 65.6 (t), 62.1 (t), 56.5 (q), 49.7 (d), 45.2 (s), 36.1 (t), 34.7 (t). Anal. Calcd for C₁₇H₁₉NO₃BrI: C, 41.49; H, 3.89; N 2.85. Found: C, 41.31; H, 4.02; N, 2.89.

(4a*R,8a*R**)-1-Bromo-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6*H*-benzofuro[3a,3,2-*ef*][2]-benzazepin-6-one (13).** **12** (300 mg, 0.61 mmol) and NaOH (300 mg, 7.50 mmol) were refluxed in 70% EtOH (10 mL) for 2 h. The solution was concentrated *in vacuo*, and the residue was partitioned between water (15 mL) and EtOAc (15 mL). The aqueous layer was extracted with EtOAc (3 x 5 mL), the combined organic layers were washed with water (2 x 20 mL) and brine (1 x 20 mL), dried (Na₂SO₄), filtered and concentrated *in vacuo*. The residue was purified by flash chromatography (SiO₂, CHCl₃ : MeOH : conc. NH₃ = 89 : 10 : 1). Yield: 112 mg (50%), colorless foam. ¹H NMR (CDCl₃): δ 7.00 (dd, *J* = 11.1 Hz, *J* = 1.3 Hz, 1H), 6.95 (s, 1H), 6.05 (d, *J* = 11.1 Hz, 1H), 4.74 – 4.65 (m, 1H), 4.23 (d, *J* = 16.9 Hz, 1H), 3.92 (d, *J* = 16.9 Hz, 1H), 3.81 (s, 3H), 3.27 - 2.82 (m, 3H), 2.75 (dd, *J* = 17.1 Hz, *J* = 5.7 Hz, 1H), 2.45 (s, 3H), 2.31 – 1.79 (m, 2H); ¹³C NMR (CDCl₃): δ 194.0 (s), 146.6 (s), 144.5 (d), 144.0 (s), 131.7 (s), 127.9 (s), 127.4 (d), 116.4 (d), 114.1 (s), 88.1 (d), 59.0 (t), 56.2 (q), 53.6 (t), 49.3 (s), 43.0 (q), 37.0 (t), 33.1 (t).

The identity with an authentic sample was confirmed by TLC, HPLC and NMR.

ACKNOWLEDGEMENTS

The authors thank Sanochemia Pharmazeutika AG for their financial support and donation of chemicals.

REFERENCES AND NOTES

1. M. Node, S. Kodama, Y. Hamashima, T. Baba, N. Hamamichi, and K. Nishide, *Angew. Chem., Int. Ed.*, 2001, **40**, 3060.
2. For a review of the acetylcholinesterase activity see: J. J. Sramek, E. J. Frackiewicz, and N. R. Cutler, *Expert Opin. Invest. Drugs*, 2000, **9**, 2393.
3. L. Czollner, J. Froehlich, U. Jordis, and B. Kueenburg, New benzazepine derivatives, medicaments containing the same and their use to prepare medicaments. WO 9740049, Oct 30, 1997.
4. M. A. H. Mucke, Froehlich, and U. Jordis, Use of galanthamine and galanthamine derivatives for the treatment of acute functional brain damage. WO 0032199, June 8, 2000.
5. M. P. V. Tato, L. Castedo, and R. Riguera, *Heterocycles*, 1988, **27**, 2833.

6. C. Muegge, B. Schablinski, K. Obst, and W. Doepke, *Pharmazie*, 1994, **49**, 444.
7. H.-G. Boit and W. Doepke, *Naturwissenschaften*, 1958, **45**, 315.
8. H.-G. Boit and H. Ehmke, *Chem. Ber.*, 1957, **90**, 369.
9. H.-G. Boit, *Chem. Ber.*, 1956, **89**, 1129.
10. W. C. Wildman and C. L. Brown, *J. Am. Chem. Soc.*, 1968, **90**, 6439.
11. M. Kihara, K. Konishi, L. Xu, and S. Kobayashi, *Chem. Pharm. Bull.*, 1991, **39**, 1849.
12. A. Machocho, S. C. Chhabra, F. Viladomat, C. Codina, and J. Bastida, *Phytochemistry*, 1999, **51**, 1185.
13. H.-G. Boit and W. Doepke, *Chem. Ber.*, 1957, **90**, 1827.
14. Y. Inubushi, H. M. Fales, E. W. Warnhoff, and W. C. Wildman, *J. Org. Chem.*, 1960, **25**, 2153.
15. H.-G. Boit and H. Ehmke, *Chem. Ber.*, 1955, **88**, 1590.
16. H.-G. Boit and H. Ehmke, *Chem. Ber.*, 1956, **89**, 2093.
17. M. A. Schwartz and R. A. Holton, *J. Am. Chem. Soc.*, 1970, **92**, 1090.
18. H.-G. Boit, *Chem. Ber.*, 1954, **87**, 1704.
19. H.-G. Boit, W. Doepke, and W. Stender, *Chem. Ber.*, 1957, **90**, 2203.
20. A. A. Ali, H. M. E. Sayed, O. M. Abdallah, and W. Steglich, *Phytochemistry*, 1986, **25**, 2399.
21. H.-G. Boit and W. Doepke, *Naturwissenschaften*, 1959, **46**, 475.
22. G. Ma, H. Li, C. Lu, X. Yang, and S. Hong, *Heterocycles*, 1986, **24**, 2089.
23. S. Ghosal, A. Razdan, and S. Razdan, *Phytochemistry*, 1985, **24**, 635.
24. M. Kihara, T. Koike, Y. Imakura, K. Kida, T. Shingu, and S. Kobayashi, *Chem. Pharm. Bull.*, 1987, **35**, 1070.
25. F. Viladomat, J. Bastida, C. Codina, W. E. Campbell, and S. Mathee, *Phytochemistry*, 1995, **40**, 307.
26. K. Tomioka, *Yakugaku Zasshi*, 1984, **104**, 1009.
27. H. W. Whitlock, W. Howard Jr., and G. L. Smith, *J. Am. Chem. Soc.*, 1967, **89**, 3600.
28. L. E. Overman and L. T. Mendelson, *J. Am. Chem. Soc.*, 1981, **103**, 5579.
29. L. E. Overman, L. T. Mendelson, and E. J. Jacobsen, *J. Am. Chem. Soc.*, 1983, **105**, 6629.
30. L. E. Overman and S. Sugai, *Helv. Chim. Acta*, 1985, **68**, 745.
31. J. B. P. A. Wijnberg and W. N. Speckamp, *Tetrahedron*, 1978, **34**, 2579.
32. T. Nishimata and M. Mori, *J. Org. Chem.*, 1998, **63**, 7586.
33. W. H. Pearson and F. E. Lovering, *J. Org. Chem.*, 1998, **63**, 3607.
34. S. F. Martin and C. L. Campbell, *J. Org. Chem.*, 1988, **53**, 3184.
35. I. H. Sanchez, F. J. Lopez, J. J. Soria, M. I. Larraza, and H. J. J. Flores, *Am. Chem. Soc.*, 1983, **105**, 7640.
36. G. E. Keck and R. R. Webb, *J. Org. Chem.*, 1982, **47**, 1302.
37. K. Tomioka, K. Koga, and S. Yamada, *Chem. Pharm. Bull.*, 1977, **25**, 2681.

38. B. F. Rose, Intramolecular oxidative coupling of monophenols. Total synthesis of (+-)-oxocrinine. Ph. D. Thesis, Florida State University, Tallahassee, Florida, USA, 1974.
39. E. Kotani, N. Takeuchi, and S. Tobinaga, *J. Chem. Soc., Chem. Commun.*, 1973, 550.
40. T. Kametani, T. Kohno, R. Charubala, S. Shibuya, and K. Fukumoto, *Chem. Pharm. Bull.*, 1972, **20**, 1488.
41. R. V. Stevens, L. E. DuPree, and P. L. Loewenstein, *J. Org. Chem.*, 1972, **37**, 977.
42. T. Kametani, T. Kohno, S. Shibuya, and K. Fukumoto, *Tetrahedron*, 1971, **27**, 5441.
43. T. Kametani, T. Kohno, S. Shibuya, and K. Fukumoto, *J. Chem. Soc. D*, 1971, 774.
44. Y. Kita, M. Arisawa, M. Gyoten, M. Nakajima, R. Hamada, H. Tohma, and T. Takada, *J. Org. Chem.*, 1998, **63**, 6625.
45. A. Goosen, E. V. O. John, F. L. Warren, and K. C. Yates, *J. Chem. Soc.*, 1961, 4038.
46. W. C. Wildman, J. C. Clardy, F. M. Hauser, D. Dahm, and R. A. Jacobson, *J. Am. Chem. Soc.*, 1970, **92**, 6337.
47. E. Erdik, *Tetrahedron*, 1987, **43**, 2203.
48. L. Czollner, W. Frantsits, B. Kueenburg, U. Hedenig, J. Froehlich, and U. Jordis, *Tetrahedron Lett.*, 1998, **39**, 2087.